# PREMARKET NOTIFICATION 510(K) SAFETY AND EFFECTIVENESS SUMMARY (as required by 21 CFR $\ S$ 807.92)

SEP 11 2012

A. 510(k)Number: K112223   
B. Purpose for Submission: New device   
C. Measurand: Anti-LKM-1 autoantibodies   
D. Type of Test: Qualitative enzyme immunoassay   
E. Applicant: EUROIMMUN US INC.   
F. Proprietary and Established Names: EUROIMMUN Anti-LKM-1 ELISA (IgG)

G. Regulatory Information:

Regulation: 21 CFR 866.5660 - Multiple autoantibodies immunological test system   
2. Classification: Class II   
3. Product code: NBS   
4. Panel: Immunology

# H. Intended Use:

1. Intended use(s): The EUROIMMUN Anti-LKM-1 ELISA (IgG) test kit is intended for the qualitative detection of IgG class autoantibodies against LKM-1 (cytochrome P450 lD6 of liver-kidney-microsomes) in human serum and plaa. Itisused as n idinthedagnosis automue hepatis, tye, in conjunction with laboratory and clinical findings.   
2. Indication(s) for use: Same as intended use.   
3. Special conditions for the use statement(s): For prescription use only.   
4. Special instrument requirements: Microwell plate reader capable of measuring OD at 450nm and at 620nm for dual wavelength readings.

# I. Device Description:

The EUROIMMUN Anti-LKM-1 ELISA (IgG) consists of a microwell ELISA plate coated with LKM-1 antigen, caliator positivead negative contro peroidase-abelle antiuan gconjga spleufrwa buffer concentrate, TMB chromogen/substrate solution and stop solution.

# J. Substantial Equivalence Information:

1. Predicate device name (s): Inova Quanta Lite LKM-1 ELISA   
2. Predicate 510(k) number(s): K000535   
3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>Detection of IgG antibodies to LKM-1 as an aid indiagnosis of autoimmune hepatitis.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Technology</td><td rowspan=1 colspan=1>ELISA</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay platform</td><td rowspan=1 colspan=1>96-well microtiter plates</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay format</td><td rowspan=1 colspan=1>Qualitative</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibration</td><td rowspan=1 colspan=1>Relative</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Antigen</td><td rowspan=1 colspan=1>Recombinant cytochrome P450 IID6.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Substrate</td><td rowspan=1 colspan=1>TMB</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reagent preparation</td><td rowspan=1 colspan=1>All reagents, calibrator and controls are ready touse, except for the wash buffer.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Procedure</td><td rowspan=1 colspan=1>Sample incubation with micro-well antigen coatedplate, followed by a wash step, incubation with ananti-human IgG enzyme conjugate; wash step.incubation with substrate; then the addition of astop solution and reading at 450nm.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Conjugate</td><td rowspan=1 colspan=1>Rabbit anti-human IgG labeled with horseradishperoxidase</td><td rowspan=1 colspan=1>Goat anti-human IgG labeled with horseradishperoxidase</td></tr><tr><td rowspan=1 colspan=1>Calibrators and controls</td><td rowspan=1 colspan=1>1 calibrator2 controls1 positive, 1 negative</td><td rowspan=1 colspan=1>3 controls1 high positive, 1 low positive, 1 negative</td></tr><tr><td rowspan=1 colspan=1>Wash buffer</td><td rowspan=1 colspan=1>10x concentrate</td><td rowspan=1 colspan=1>40x concentrate</td></tr><tr><td rowspan=1 colspan=1>Stop solution</td><td rowspan=1 colspan=1>0.5 M sulphuric acid</td><td rowspan=1 colspan=1>0.344 M sulphuric acid</td></tr><tr><td rowspan=1 colspan=1>Sample types and dilution</td><td rowspan=1 colspan=1>Serum or plasma1:101 dilution</td><td rowspan=1 colspan=1>Serum1:101 dilution</td></tr><tr><td rowspan=1 colspan=1>Reported results</td><td rowspan=1 colspan=1>Ratio</td><td rowspan=1 colspan=1>Units</td></tr><tr><td rowspan=1 colspan=1>Cut off level</td><td rowspan=1 colspan=1>Ratio 1.0</td><td rowspan=1 colspan=1>25 Units</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

None referenced.

# L. Test Principle:

Patient samples are diluted 1:101 in sample buffer, $1 0 0 ~ \mu \up$ of each diluted patient sample and pre-diluted controls and calibrator are added to the antigen coated microtiter wells and incubated or 30minutes at rom temperature. After incubation the microtiter well strips are washed with wash buffer to remove unbound antibodies and $1 0 0 \mu \nu$ of the anti-human IgG enzyme conjugate reagent is added to each microtiter well. After an additional 30-minutes incubation at room temperature, the microtiter wells are again washed 3 times with $3 0 0 ~ \mu 1$ of wash buffer to remove any unbound enzyme conjugate and $1 0 0 ~ \mu \vert$ of the chromogen substrate is added. The strips are incubated for 15 minutes at room temperature and $1 0 0 ~ \mu !$ stop solution is added. The microtiter plates are placed in an ELISA reader and read at a wavelength of 450 nm and a reference wavelength of between 620 nm and 650 nm within 30 minutes.

# M. Performance Characteristics (where applicable):

1. Analytical performance:

a. Precision/Reproducibility:

The reproducibility of the test was investigated with samples at different points on the calibration curve. Intra-assay reproducibility is based on 20 determinations and inter-assay reproducibility on 24 determinations performed in 6 different runs (days) according to the package insert. Both intra-assay and inter-assay reproducibility were found to be sufficient as no positive sample was found negative and vice versa (except for a single determination of a negative sample that was very close to the cutoff). The following results were obtained:

# Intra-assay reproducibility

Inter-assay reproducibility   

<table><tr><td rowspan=2 colspan=1>n = 20</td><td rowspan=1 colspan=6>Anti-LKM-1 ELISA (IgG)Ratio</td></tr><tr><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>Sample 4</td><td rowspan=1 colspan=1>Sample 5</td><td rowspan=1 colspan=1>Sample 6</td></tr><tr><td rowspan=1 colspan=1>Mean value (x):</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>4.7</td></tr><tr><td rowspan=1 colspan=1>Range of values:</td><td rowspan=1 colspan=1>0.2-0.2</td><td rowspan=1 colspan=1>0.7-0.8</td><td rowspan=1 colspan=1>1.1-1.3</td><td rowspan=1 colspan=1>1.8-2.0</td><td rowspan=1 colspan=1>2.9-3.2</td><td rowspan=1 colspan=1>4.1-5.0</td></tr><tr><td rowspan=1 colspan=1>Expected result:</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td></tr></table>

<table><tr><td rowspan=2 colspan=1>n = 24</td><td rowspan=1 colspan=6>Anti-LKM-1 ELISA (IgG)Ratio</td></tr><tr><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>Sample 4</td><td rowspan=1 colspan=1>Sample 5</td><td rowspan=1 colspan=1>Sample 6</td></tr><tr><td rowspan=1 colspan=1>Mean value (x):</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>4.6</td></tr><tr><td rowspan=1 colspan=1>Range of values:</td><td rowspan=1 colspan=1>0.2-0.3</td><td rowspan=1 colspan=1>0.7-1.0</td><td rowspan=1 colspan=1>1.0- 1.3</td><td rowspan=1 colspan=1>1.5-2.2</td><td rowspan=1 colspan=1>2.4-3.4</td><td rowspan=1 colspan=1>3.9-5.2</td></tr><tr><td rowspan=1 colspan=1>Expected result:</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>4%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>96%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0%</td></tr></table>

The Lot to Lot reproducibiity was investigatedduring the validaton and quality control of he kising different lots with QC samples distributed over the measurement range. Lot to lot reproducibility was found to be sufficient as no positive sample was found negative and vice versa. The following results were obtained:

# Lot to lot reproducibility

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=10>Anti-LKM-1 ELISA (IgG)Ratio</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=2>Sample 2</td><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=2>Sample 4</td><td rowspan=1 colspan=1>Sample 5</td><td rowspan=1 colspan=2>Sample 6</td><td rowspan=1 colspan=1>Sample 7</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=2>6</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=2>6</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=2>6</td><td rowspan=1 colspan=1>6</td></tr><tr><td rowspan=1 colspan=1>Mean value (x):</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=2>1.2</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=2>2.4</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=2>4.8</td><td rowspan=1 colspan=1>5.8</td></tr><tr><td rowspan=1 colspan=1>Range of values:</td><td rowspan=1 colspan=1>0.9-0.9</td><td rowspan=1 colspan=2>1.2-1.4</td><td rowspan=1 colspan=1>1.6-1.8</td><td rowspan=1 colspan=2>2.3-2.5</td><td rowspan=1 colspan=1>2.8-3.0</td><td rowspan=1 colspan=2>4.5-5.1</td><td rowspan=1 colspan=1>5.7-6.0</td></tr><tr><td rowspan=1 colspan=1>Expected result:</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=2>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=2>positive</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=2>positive</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=2>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=2>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=2>100%</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=2>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=2>0%</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=2>0%</td><td rowspan=1 colspan=1>0%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=10>Anti-LKM-1 ELISA (IgG)Ratio</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=2>Sample 8</td><td rowspan=1 colspan=3>Sample 9</td><td rowspan=1 colspan=3>Sample 10</td><td rowspan=1 colspan=2>Sample 11</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=2>32</td><td rowspan=1 colspan=3>7</td><td rowspan=1 colspan=3>14</td><td rowspan=1 colspan=2>8*</td></tr><tr><td rowspan=1 colspan=1>Mean value (x):</td><td rowspan=1 colspan=2>7.3</td><td rowspan=1 colspan=3>8.0</td><td rowspan=1 colspan=3>0.1</td><td rowspan=1 colspan=2>0.1</td></tr><tr><td rowspan=1 colspan=1>Range of values:</td><td rowspan=1 colspan=2>5.5-8.3</td><td rowspan=1 colspan=3>7.2-8.7</td><td rowspan=1 colspan=3>0.1-0.1</td><td rowspan=1 colspan=2>0.1-0.2</td></tr><tr><td rowspan=1 colspan=1>Expected result:</td><td rowspan=1 colspan=2>positive</td><td rowspan=1 colspan=3>positive</td><td rowspan=1 colspan=3>negative</td><td rowspan=1 colspan=2>negative</td></tr><tr><td rowspan=1 colspan=1>% positive:</td><td rowspan=1 colspan=2>100%</td><td rowspan=1 colspan=3>100%</td><td rowspan=1 colspan=3>0%</td><td rowspan=1 colspan=2>0%</td></tr><tr><td rowspan=1 colspan=1>% negative:</td><td rowspan=1 colspan=2>0%</td><td rowspan=1 colspan=3>0%</td><td rowspan=1 colspan=3>100%</td><td rowspan=1 colspan=2>100%</td></tr></table>

\*3 lots x 2 runs \*\* n lots x 1 run

b. Linearity/assay reportable range: Not applicable.   
C. Traceability, Stability, Expected values (controls, calibrators or methods): There is no recognized standard or reference material for anti-SLA/LP antibodies. Results are given as ratios.

d. Detection limit:

Not applicable.

e. Analytical specificity:

Cross-reactivity: Cross reactivity was investigated using a panel of 28 sera serologically positive for antibodies against SLALP. All 28 sera were negative in the Anti-LKM-1 ELISA (IgG), so no cross reactivity is expected.

Interference: To investigate the influence from hemoglobin, triglycerides and bilirubin, 5 different specimens at different anti-LKM-1 concentrations (ratio 1.1 - 9.3) were spiked with potential interfering substances and were incubated with the test system. The recovery in relation to the unspiked sample without interferent was calculated. The individual recovery was within the range of 86 - $126 \%$ . No significant interference was observed for concentrations of up to 1000 mg/dl for hemoglobin, $2 0 0 0 m g / d 1$ for triglyceride and $4 0 m g / d 1$ for bilirubin.

f. Assay cut-off. Ratio 1.0

2Comparison studies:

a. Method comparison with predicate device.

A study was performed in cooperation with a university clinical hospital comparing the performance of the EUROiMMUN Anti-LKM-1 ELISA (IgG) and an FDA released predicate device. 167 samples were investigated (58 from AIH patients, 66 from PBC patients, 15 from patients with AlH/PBC overlap syndrome and 28 from patients with viral hepatitis). The panel consisted of 30 men and 137 women. Age ranged from 1 to 87 years with an average age of 50 years. To cover the lower range with more samples, additional 29 samples were created by mixing of positive and negative samples.

<table><tr><td colspan="2" rowspan="2">n = 196</td><td colspan="4">Predicate ELISA</td></tr><tr><td>positive</td><td>borderline</td><td>negative</td></tr><tr><td rowspan="2">EUROIMMUN Anti-SLA/LP ELISA (IgG)</td><td colspan="2">positive</td><td></td><td>0</td></tr><tr><td colspan="2">negative</td><td>0</td><td>5 155</td></tr><tr><td>Negative agreement 155</td><td>1 160</td><td>1 = 96.9%</td><td>95% C.I.:</td><td>92.9%</td></tr><tr><td>Positive agreement 35</td><td>/ 36</td><td>= 97.2%</td><td>95% C.I.:</td><td>99.0% 85.5%</td></tr><tr><td>Overall agreement 190</td><td>1 196</td><td>= 96.9%</td><td>95% C.I.: 93.5%</td><td>99.99 98.99</td></tr></table>

b. Matrix comparison:

The usability of plasma was investigated using 16 sample pairs each of serum and corresponding plasma. The samples cover concentrations in the diagnostically important range and the cut-off. Passing-Bablok regression was calculated for the comparison of serum to plasma. The results are shown in the table below.

<table><tr><td></td><td>EDTA plasma</td><td>Heparin plasma</td><td>Citrate plasma</td></tr><tr><td>Regression equation (y = plasma, x = serum)</td><td>y = 0.02 + 1.00 x</td><td>y = -0.00 + 1.00 x</td><td>y = 0.00 + 0.97</td></tr><tr><td>95% C.I. of intercept</td><td>-0.04 to 0.06</td><td>-0.03 to 0.06</td><td>-0.06 to 0.05</td></tr><tr><td>95% C.I. of slope</td><td>0.98 to 1.02</td><td>0.97 to 1.01</td><td>0.95 to 1.00</td></tr></table>

A comparison in which the $9 5 \%$ C.I. of the slope contains 1.0 and the $9 5 \%$ C.I. of the intercept contains 0 indicates equivalence of concentration between serum and the corresponding plasma matrices. The comparison above satisfies this condition.

Coefficients of determination were found to be above 0.99 and $\%$ BIAS from serum was in the range of 87 to $109 \%$ (serum $= 1 0 0 \%$ i

3Clinical studies:

In a clinical/diagnostical study, performed in cooperation with several university, hospital and private laboratories, in total 515 clinically characterized samples (68 from AlH-2 patients, 65 from AlH-1 patients, 15 from patients with AlH/P8C overlap syndrome and 367 from other control groups) were investigated for anti-LKM-1 antibodies (IgG). The EUROIMMUN Anti-LKM-1 ELISA (IgG) showed a sensitivity for AIH type 2 of $9 5 . 6 \%$ $( 9 5 \% \mathbb { C } . 1 . ; 8 7 . 6 - 9 9 . 1 \% )$ .The specificity was $100 . 0 \%$ $9 5 \%$ C.I.: 99.2 - 100.0%).

aClinical sensitivity.

<table><tr><td rowspan=2 colspan=1>No.</td><td rowspan=2 colspan=1>Panel</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=3>Anti-LKM-1 ELISA (IgG)</td></tr><tr><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>95% C.I.</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>Autoimmune hepatitis type 2 (AlH-2)</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>65</td><td rowspan=1 colspan=1>95.6%</td><td rowspan=1 colspan=1>87.6- 99.1%</td></tr></table>

Clinical specificity:

<table><tr><td rowspan=2 colspan=1>No.</td><td rowspan=2 colspan=1>Panel</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=2>Anti-LKM-1 ELISA (IgG)</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>95% C.I.</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>AlH/PBC overlap syndrome</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>78.2-100.0%</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>Autoimmune hepatitis type 1 (AlH-1)</td><td rowspan=1 colspan=1>65</td><td rowspan=1 colspan=1>65</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>94.5- 100.0%</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>Viral hepatitis</td><td rowspan=1 colspan=1>118</td><td rowspan=1 colspan=1>118</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>96.9- 100.0%</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>Toxic liver damages</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>76.8- 100.0%</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>Steatohepatitis</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>85.8 - 100.0%</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>Primary biliary liver cirrhosis (PBC)</td><td rowspan=1 colspan=1>111</td><td rowspan=1 colspan=1>111</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>96.7 - 100.0%</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>Primary sclerosing cholangitis (PSC)</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>82.4-100.0%</td></tr><tr><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>Other autoimmune diseases*</td><td rowspan=1 colspan=1>81</td><td rowspan=1 colspan=1>81</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>95.5- 100.0%</td></tr><tr><td rowspan=1 colspan=1>â€¢</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>447</td><td rowspan=1 colspan=1>447</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>99.2 - 100.0%</td></tr></table>

\*from the following groups: MCTD $( n = 2 0 )$ ; celiac disease $( \pmb { \mathsf { n } } = 1 1 )$ Diabetes Type I $( n = 1 2 )$ , Hashimoto $( n = 1 1 )$ , Grave's disease $( \boldsymbol { \mathsf { n } } = 1 2 )$ , ulcerative colitis $( n = 1 5 )$ EMPY

c. Other clinical supportive data (when a. and b. are not applicable):

4Clinical cut-off:

See Assay cut-off.

5. Expected values/Reference range:

The levels of anti-LKM-1 antibodies (IgG) were analyzed with the EUROIMMUN Anti-LKM-1 ELISA (igG) in a panel of 150 apparently healthy blood donors (mixed age and sex). With a cut-off of ratio 1.0, only one blood donor was found positive.

<table><tr><td rowspan=1 colspan=1>Positives</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Negatives</td><td rowspan=1 colspan=1>149</td></tr><tr><td rowspan=1 colspan=1>Lowest value</td><td rowspan=1 colspan=1>Ratio 0.0</td></tr><tr><td rowspan=1 colspan=1>Highest value</td><td rowspan=1 colspan=1>Ratio 3.4</td></tr><tr><td rowspan=1 colspan=1>Mean value</td><td rowspan=1 colspan=1>Ratio 0.2</td></tr><tr><td rowspan=1 colspan=1>Std dev. (SD)</td><td rowspan=1 colspan=1>Ratio 2.29</td></tr><tr><td rowspan=1 colspan=1>$95^{}$percentile</td><td rowspan=1 colspan=1>0.4</td></tr><tr><td rowspan=1 colspan=1>99thpercentile</td><td rowspan=1 colspan=1>0.8</td></tr></table>

V. Proposed Labeling: The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalenc decision.

EUROIMMUN US Inc. c/o Ms. Kathryn Kohl Managing Director 1 100 The American Road Morris Plains, NJ 07950

Re: k112223 Trade/Device Name: EUROIMMUN Anti-LKM-1 (IgG) Regulation Number: 21 CFR 866.5660 Regulation Name: Multiple autoantibodies immunological test system Regulatory Class: Class II Product Code: NBS Dated: September 5, 2012 Received: September 7, 2012

Dear Ms. Kohl:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of

medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796- 5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

![](images/4d8463c2cb8581e6a3c9e461a32168955cde98623358acb220d25f88a2d159cb.jpg)

Maria Chan, Ph.D.   
Director   
Division of Immunology and Hematology Devices Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

Enclosure

# Indications for Use

510(k) Number (if known): K112223

Device Name: Anti-LKM-1 ELISA (IgG)

Indications For Use:

The EUROIMMUN Anti-LKM-1 ELISA (IgG) test kit is intended for the qualitative detection of IgG class autoantibodies against LKM-1 (cytochrome P450 lID6 of liverkidney-microsomes) in human serum and plasma. It is used as an aid in the diagnosis of autoimmune hepatitis, type 2, in conjunction with other laboratory and clinical findings.

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

![](images/1496bc9a88a3315761d16f7aaee708d0197e159b4b86e41d915d56e78e929af6.jpg)

# Division Sign-Off

Page 1 of_

Office of In Vitro Diagnostic Device Evaluation and Safety 510K K112223